Evidence map›Paper›PMID 34204102›Full record

ArticleCancers2021

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (

Richard L Wahl, Eric C Frey, Heather A Jacene, Brad S Kahl, Steven Piantadosi, Jesus A Bianco, Richard J Hammes, Miah Jung, Wayne Kasecamp, Bin He and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  2. Theranostics and Patient-Specific Dosimetry.Seminars in radiation oncology · 2023
    Review
  3. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
  4. Radionuclides for Targeted Therapy: Physical Properties.Molecules (Basel, Switzerland) · 2022
    Review
  5. Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  6. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Richard L WahlSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-7306-2590
Eric C FreySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-9596-3955
Heather A JaceneDivision of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
Brad S KahlDepartments of Medicine and Radiology, University of Wisconsin Medical School, Madison, WI 53706, USA.
Steven PiantadosiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Jesus A BiancoDivision of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
Richard J HammesDepartments of Medicine and Radiology, University of Wisconsin Medical School, Madison, WI 53706, USA.
Miah JungSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Wayne KasecampDivision of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
Bin HeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
George SgourosDivision of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
Ian W FlinnSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Lode J SwinnenSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Johns Hopkins University · USUniversity of Wisconsin–Madison · USBrigham and Women's Hospital · USHarvard University · US

Funding

NIH HHS 5P30CA006973NIH HHS 5P50CA096888-
6 · The paper itself

Abstract

purposeWe prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin's lymphoma using the theranostic pair of

methods24 patients with CD20-positive relapsed or refractory rituximab-sensitive, low-grade, mantle cell, or diffuse large-cell NHL, with normal organ function, platelet counts > 75,000/mm

resultsPatient-specific hybrid SPECT/CT + planar organ dosimetry was feasible in all 18 cases and used to determine the patient-specific therapeutic dose and guide dose escalation (26.8 ± 7.3 MBq/kg (mean), 26.3 MBq/kg (median) of

conclusionsPatient-specific outpatient

Indexed as

anti CD20dosimetrylymphomaquantitative SPECT imagingradioimmunotherapytheranostics

Identifiers

PMID34204102
PMCPMC8201215
OpenAlexW3171781970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.